About: Lessons from Corporate Influence in the Opioid Epidemic: Toward a Norm of Separation

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Lessons from Corporate Influence in the Opioid Epidemic: Toward a Norm of Separation Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Lessons from Corporate Influence in the Opioid Epidemic: Toward a Norm of Separation
Creator	Marks, Jonathan
Source	Medline; PMC
abstract	There is overwhelming evidence that the opioid crisis—which has cost hundreds of thousands of lives and trillions of dollars (and counting)—has been created or exacerbated by webs of influence woven by several pharmaceutical companies. These webs involve health professionals, patient advocacy groups, medical professional societies, research universities, teaching hospitals, public health agencies, policymakers, and legislators. Opioid companies built these webs as part of corporate strategies of influence that were designed to expand the opioid market from cancer patients to larger groups of patients with acute or chronic pain, to increase dosage as well as opioid use, to downplay the risks of addiction and abuse, and to characterize physicians’ concerns about the addiction and abuse risks as “opiophobia.” In the face of these pervasive strategies, conflict of interest policies have proven insufficient for addressing corporate influence in medical practice, medical research, and public health policy. Governments, the academy, and civil society need to develop counterstrategies to insulate themselves from corporate influence and to preserve their integrity and public trust. These strategies require a paradigm shift—from partnerships with the private sector, which are ordinarily vehicles for corporate influence, to a norm of separation.
has issue date	2020-07-13(xsd:dateTime)
bibo:doi	10.1007/s11673-020-09982-x
bibo:pmid	32661741
has license	no-cc
sha1sum (hex)	63203024645efcbc1ef944a16bc8fca77753fbec
schema:url	https://doi.org/10.1007/s11673-020-09982-x
resource representing a document's title	Lessons from Corporate Influence in the Opioid Epidemic: Toward a Norm of Separation
has PubMed Central identifier	PMC7357445
has PubMed identifier	32661741
schema:publication	J Bioeth Inq
resource representing a document's body	covid:63203024645efcbc1ef944a16bc8fca77753fbec#body_text
is schema:about of	named entity 'counting' named entity 'public health' named entity 'influence' named entity 'groups' named entity 'teaching hospitals' named entity 'Norm' named entity 'TO INCREASE' named entity 'MARKET' named entity 'PATIENT ADVOCACY' named entity 'TRUST' named entity 'PATIENTS' named entity 'THEIR' named entity 'PRIVATE SECTOR' named entity 'DOLLARS' named entity 'TO CHARACTERIZE' named entity 'PHARMACEUTICAL' named entity 'SOCIETY' named entity 'INTEGRITY' named entity 'MEDICAL RESEARCH' named entity 'RISKS' named entity 'INFLUENCE' named entity 'WEBS' named entity 'CONFLICT OF INTEREST' named entity 'COMPANIES' named entity 'academy' named entity 'professional societies' named entity 'risks' named entity 'evidence' named entity 'lives' named entity 'hundreds' named entity 'There' named entity 'strategies' named entity 'develop' named entity 'Lessons' named entity 'health professionals' named entity 'chronic pain' named entity 'private sector' named entity 'research universities' named entity 'teaching hospitals' named entity 'opioid' named entity 'corporate strategies' named entity 'corporate influence' named entity 'opioid crisis' named entity 'public health policy' named entity 'Opioid Epidemic' named entity 'Corporate Influence' named entity 'public officials' named entity 'drug companies' named entity 'MGH' named entity 'political influence' named entity 'active ingredients' named entity 'Purdue Pharma' named entity 'health professionals' named entity 'political action committees' named entity 'opioid' named entity 'Oklahoma' named entity 'opioid' named entity 'United States' named entity 'North America' named entity 'pharmaceutical sector' named entity 'corporate influence' named entity 'U.S. Senate' named entity 'United States' named entity 'opioid' named entity 'corporate influence' named entity 'corporate influence' named entity 'electronic health records' named entity 'OxyContin' named entity 'opioid' named entity 'corporate influence' named entity 'Sackler family' named entity 'public relations' named entity 'public domain' named entity 'pharmaceutical companies' named entity 'opioids' named entity 'Purdue Pharma' named entity 'commercial practices' named entity 'NIDA' named entity 'paradigm shift' named entity 'Massachusetts' named entity 'commercial interests'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software